These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 23919444)

  • 1. Budget impact analysis of 8 hormonal contraceptive options.
    Crespi S; Kerrigan M; Sood V
    Am J Manag Care; 2013 Jul; 19(7):e249-55. PubMed ID: 23919444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of levonorgestrel subdermal implants. Comparison with other contraceptive methods available in the United States.
    Ashraf T; Arnold SB; Maxfield M
    J Reprod Med; 1994 Oct; 39(10):791-8. PubMed ID: 7837126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration-approved duration.
    McNicholas C; Swor E; Wan L; Peipert JF
    Am J Obstet Gynecol; 2017 Jun; 216(6):586.e1-586.e6. PubMed ID: 28147241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and cost of contraception in France (FACET study): a cohort study from the French National Healthcare Insurance Database.
    Agostini A; Godard C; Laurendeau C; Benmahmoud A; Lafuma A; Doz M; Lévy-Bachelot L; Gourmelen J; Linet T
    Eur J Obstet Gynecol Reprod Biol; 2018 Oct; 229():137-143. PubMed ID: 30176517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter randomized clinical trial of one-rod etonogestrel and two-rod levonorgestrel contraceptive implants with nonrandomized copper-IUD controls: methodology and insertion data.
    Meirik O; Brache V; Orawan K; Habib NA; Schmidt J; Ortayli N; Culwell K; Jackson E; Ali M;
    Contraception; 2013 Jan; 87(1):113-20. PubMed ID: 23063337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative cost effectiveness of Depo-Provera, Implanon, and Mirena in reversible long-term hormonal contraception in the UK.
    Varney SJ; Guest JF
    Pharmacoeconomics; 2004; 22(17):1141-51. PubMed ID: 15612832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ethinylestradiol + etonogestrel contraceptive vaginal ring: new drug. Possibly useful in some situations.
    Prescrire Int; 2006 Apr; 15(82):50-3. PubMed ID: 16604729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost-effectiveness of long-acting reversible contraceptive methods in the UK: analysis based on a decision-analytic model developed for a National Institute for Health and Clinical Excellence (NICE) clinical practice guideline.
    Mavranezouli I;
    Hum Reprod; 2008 Jun; 23(6):1338-45. PubMed ID: 18372257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acceptability of IUDs is increasing.
    Finger WR; Barr D
    Netw Res Triangle Park N C; 1992 Oct; 13(2):27-30. PubMed ID: 12286082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrauterine devices: an effective alternative to oral hormonal contraception.
    Prescrire Int; 2009 Jun; 18(101):125-30. PubMed ID: 19637436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Achieving cost-neutrality with long-acting reversible contraceptive methods.
    Trussell J; Hassan F; Lowin J; Law A; Filonenko A
    Contraception; 2015 Jan; 91(1):49-56. PubMed ID: 25282161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postcoital contraception: present and future options.
    Derman SG; Peralta LM
    J Adolesc Health; 1995 Jan; 16(1):6-11. PubMed ID: 7742340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost effectiveness of contraceptives in the United States.
    Trussell J; Lalla AM; Doan QV; Reyes E; Pinto L; Gricar J
    Contraception; 2009 Jan; 79(1):5-14. PubMed ID: 19041435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post coital contraception.
    Haspels AA; Van Santen MR
    J Gynaecol Endocrinol; 1986; 2(1-2):17-24. PubMed ID: 12269214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IUDs, implants, Depo-Provera have "incredible return on investment".
    Contracept Technol Update; 1995 Jul; 16(7):81-4. PubMed ID: 12346506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of the etonogestrel implant and levonorgestrel intrauterine device beyond the U.S. Food and Drug Administration-approved duration.
    McNicholas C; Maddipati R; Zhao Q; Swor E; Peipert JF
    Obstet Gynecol; 2015 Mar; 125(3):599-604. PubMed ID: 25730221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose progestin-releasing contraceptives are associated with a higher pain threshold in healthy women.
    Máximo MM; Silva PS; Vieira CS; Gonçalvez TM; Rosa-E-Silva JC; Candido-Dos-Reis FJ; Nogueira AA; Poli-Neto OB
    Fertil Steril; 2015 Nov; 104(5):1182-9. PubMed ID: 26341277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Considerations for the use of progestin-only contraceptives.
    Freeman S; Shulman LP
    J Am Acad Nurse Pract; 2010 Feb; 22(2):81-91. PubMed ID: 20132366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world cost-effectiveness of etonogestrel implants compared to long-term and short term reversible contraceptive methods in France.
    Linet T; Lévy-Bachelot L; Farge G; Crespi S; Yang JZ; Robert J; Fabron C
    Eur J Contracept Reprod Health Care; 2021 Aug; 26(4):303-311. PubMed ID: 33960248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The end of IUD marketing in the United States: what does it mean for American women?].
    Forrest JD
    Contracept Fertil Sex (Paris); 1987 Mar; 15(3):291-300. PubMed ID: 12341479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.